– Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise – 3Q23 DAYBUE ™ (trofinetide) net product sales of $66.9 million – 3Q23 NUPLAZID ® (pimavanserin) net product sales of $144.8 million SAN DIEGO –(BUSINESS WIRE)–Nov.
News Category: Earnings News
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
– 2Q23 DAYBUE ™ (trofinetide) net product sales of $23.2 million – 2Q23 NUPLAZID ® (pimavanserin) net product sales of $142.0 million – Expanded licensing agreement for trofinetide includes ex-North American rights SAN DIEGO –(BUSINESS WIRE)–Aug. 2, 2023– Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
– 1Q23 NUPLAZID ® net sales of $118.5 million – Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 – Announced DAYBUE Availability on April 17, 2023 SAN DIEGO –(BUSINESS WIRE)–May
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
– Full year 2022 net sales of $517.2 million , an increase of 7% over 2021 – Prescription Drug User Fee Act (PDUFA) action date set for March 12, 2023 , for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Feb. 27, 2023– Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
– 3Q22 net sales of $130.7 million – Prescription Drug User Fee Act action date set for March 12, 2023 for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Nov. 2, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
– 2Q22 net sales of $134.6 million , a 17% increase over 2Q21 – NDA submitted for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Aug. 8, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022 .
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
– 1Q22 net sales of $115.5 million , an 8% increase over 1Q21 – Reiterating FY22 net sales guidance of $510 to $560 million – FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022 SAN DIEGO –(BUSINESS WIRE)–May 4, 2022– Acadia
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
SAN DIEGO –(BUSINESS WIRE)–Apr. 18, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
– Full year 2021 net sales grew to $484.1 million , a 10% increase over 2020 – Resubmitted sNDA for pimavanserin for the treatment of Alzheimer’s disease psychosis – Delivered positive top-line results from the pivotal Phase 3 Lavender trial evaluating trofinetide for the treatment of Rett syndrome
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
– Trofinetide met co-primary efficacy endpoints demonstrating statistically significant improvement over placebo in the Rett Syndrome Behaviour Questionnaire (RSBQ) (p=0.0175) and the Clinical Global Impression of Improvement (CGI-I) (p=0.0030) – Trofinetide met key secondary endpoint demonstrating